Mandalam Ramkumar sold $358K of CYRX

Mandalam Ramkumar sold 23,214 shares of Cryoport, Inc. (CYRX) at $15.44 ($0.36M total) on 2026-06-08.

Original reporting
SEC EDGAR · Mandalam Ramkumar
Published Jun 9, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CYRX
Neutral
high confidence
Mentioned
$CYRX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYRXNeutralLow
01

Why it matters

This adds a fresh datapoint on director selling activity (23,214 shares sold), but it does not introduce new company fundamentals, guidance, or regulatory/contract developments.

02

Market read

Traders may monitor CYRX insider activity, but the disclosure alone is unlikely to drive a sustained repricing without corroborating fundamental catalysts.

03

What to watch

The article provides only the sale details; it does not include context on total insider holdings, prior sales cadence, or any concurrent company-specific news.

Relevance 4/10Novelty 6/10Timing: filed 2026-06-08 (after-hours)

Background

The article is an SEC Form 4 insider transaction disclosure for Cryoport, Inc. (CYRX).

Company-level read

Ticker impact

$CYRXNeutralHigh confidence
Context

Cryoport director Mandalam Ramkumar filed an open-market sale of 23,214 shares at $15.4412 on 2026-06-08 (Form 4).

Expected impact

Low near-term impact; any effect is likely short-lived and outweighed by broader company fundamentals.

Evidence & confidence

The filing is a director open-market sale with no 10b5-1 plan stated and no new operating/financial information disclosed in the text.

Market effects

Minimal; single-company insider transaction without sector-wide read-across.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/tax needs; without a stated 10b5-1 plan, the sale still may not reflect bearish fundamentals.

Key entities

  • Cryoport, Inc.

    Subject of the Form 4 insider transaction disclosure (CYRX).

  • Mandalam Ramkumar

    Director who sold 23,214 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CYRXMed

CryoPort Q3 Earnings Call Highlights

CryoPort reported Q3 supporting 23 commercial therapies and 788 clinical trials. China operations contribute 3-4% of revenue. The company expects five regulatory filings and two potential new therapy approvals in 2026. Guidance is conservative, focusing on existing clients. Expansion plans include new BioServices capabilities in Paris and California, with long-term margin goals of 55% gross and 30% adjusted EBITDA.

$CYRXMed

Cryoport Reports Third Quarter 2026 Financial Results

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Third Quarter 2026 Financial Results · Third quarter revenue grew 14% year-over-year to $50.2 million · Commercial Cell and Gene Therapy revenue increased 20% year-over-year · Supporting a record 788 global clinical trials and 23 commercially approve

$CYRXMedAI 8/10

Cryoport (CYRX) Q2 2026 Earnings Call Transcript

Cryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.

$CYRXMed

Cryoport Reports Second Quarter 2026 Financial Results

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 25% year-over-year · Supporting 779 global clin